AUSTIN, Texas–(BUSINESS WIRE)–Acessa Health Inc. announced today that it has acquired the Acessa® System for the treatment of symptomatic uterine fibroids, following the close of an asset purchase agreement with Halt Medical Inc. Concurrent with the acquisition, Acessa Health completed the first closing of a planned $30 million Series A […]
Author: Ken Dropiewski
BioSig Technologies Release: Novel Findings Obtained With The PURE EP System To Be Presented At American Heart Association’s BCVS Scientific Sessions 2017
Minneapolis, MN, June 26, 2017 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need for the $4+ billion electrophysiology (EP) marketplace, today announced that the American Heart Association’s 13th Annual Basic Cardiovascular Sciences (BCVS) 2017 Scientific […]
Heart Endovascular & Rhythm of Texas Begins First Commercial, FDA-Cleared, In-Patient Use of DABRA™ to Treat Peripheral Artery Disease
SAN ANTONIO–(BUSINESS WIRE)–Today, the Heart Endovascular & Rhythm of Texas announced its latest collaboration with Ra Medical Systems, makers of cardiovascular and dermatology catheters and excimer lasers, to use its groundbreaking DABRA™ System for the treatment of Peripheral Artery Disease (PAD) in order to combat the growing rise of diabetic […]
Teleflex (TFX) Announces 510(k) Clearance and Global Launch of Twin-Pass® Torque Dual Access Catheter
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced 510(k) clearance by the Food and Drug Administration and both U.S. and international commercial launch of the Twin-Pass Torque Dual Access Catheter. “The Twin-Pass Torque Catheter builds on Vascular Solutions’ […]
BioImage-2 Starts: Ultrasound Imaging for Cardiac Risk Prediction Looks at Disease Progression
NEW YORK, June 20, 2017 /PRNewswire/ — Mount Sinai Heart and BioImage-2 LLC, today announced start of the BioImage-2 study. The BioImage-2 study investigates the progression of vascular atherosclerotic plaque in patients who previously participated in the BioImage study. That landmark study recruited 7,687 volunteer participants from Humana members in Greater […]
Millar, Inc. Sells Inca® Pressure-Volume (PV) Loop System to the University of Colorado to Support LVAD Research
HOUSTON, June 22, 2017 /PRNewswire/ — Millar, Inc. is pleased to announce that the University of Colorado Anschutz Medical Campus has purchased the CD Leycom® Inca® Pressure-Volume (PV) Loop System – sold in North America exclusively by Millar, Inc. – to better understand how left ventricular assist devices (LVADs) impact ventricular function […]
Italian Boy Becomes Youngest Patient Bridged To Transplant With The SynCardia Total Artificial Heart
The smaller 50cc Total Artificial Heart helped rejuvenate the critically-ill 12-year-old’s vital organs until a matching donor heart became available two weeks later. TUCSON, Ariz.–(BUSINESS WIRE)–A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be bridged to a heart transplant with […]
Merit Medical (MMSI)’s Embosphere Microspheres Receive FDA 513(F)(2) (De Novo) Classification For Prostatic Artery Embolization Indication
SOUTH JORDAN, Utah, June 22, 2017 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy, today announced that it has received 513(f)(2) (de novo) classification from the FDA to […]
TriReme Medical Reports Negative Late Lumen Loss At 24-Month Angiographic Follow-Up For Chocolate Heart™ Drug-Coated Coronary Balloon
PLEASANTON, Calif., June 21, 2017 /PRNewswire/ — TriReme Medical LLC (the “Company”), a subsidiary of QT Vascular Ltd, announced today its angiographic data from 24-month follow-up of patients with De Novo lesions treated with Chocolate Heart™ as a standalone therapy. The initial six-month results were announced on 5 January 2016. Chocolate Heart™ […]
EBR Systems Awarded Favorite Innovation For Wise CRT At 2017 EHRA Europace Cardiostim Congress
SUNNYVALE, Calif.–(BUSINESS WIRE)–EBR Systems, Inc., developer of the world’s smallest, wireless, implantable device for cardiac pacing, today announced that WiSE CRT received the Favorite Innovation Award for its second-generation system at the 2017 EHRA Europace Cardiostim congress in Vienna, Austria. Cardiostim Innovation Awards are selected by an international panel of […]



